Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999. Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.
History
MMV was launched in 1999, with initial seed funding of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, the World Bank, and the Rockefeller Foundation.
Governance
MMV is governed by a board of directors. The Chairman of MMV is Mr Alan Court. MMV has a board of directors in North America, an Expert Scientific Advisory Committee which helps to identify projects, an Access & Product Management Advisory Committee and a Global Safety Board which reviews projects.
Projects
MMV's project portfolio states that their goals are:
- Effective treatment against drug-resistant strains of Plasmodium falciparum
- The potential for intermittent treatments (infants and pregnancy)
- Safety for small children (less than 6 months old)
- Safety in pregnancy
- Effective treatment against Plasmodium vivax (including radical cure)
- Effective treatment against severe malaria
- and transmission-blocking treatment.
Open Source Malaria
MMV started the Open Source Malaria project, which encourages people to share procedures and results of open source research. The Open Source Malaria, with researchers at the University of Sydney, supervised high school students at Sydney Grammar School who adapted a synthesis of Daraprim (pyrimethamine) using a less hazardous method.
References
External links
- Official website
- Medicine for Malaria Venture's Project Portfolio
- Roll Back Malaria Progress and Impact Series
